A Phase 2 Open-Label, Sequential Dose Escalation Study to Evaluate the Efficacy, Pharmacokinetics and Safety of Three Volumes (1.25, 2.50 and 3.75 mL) of Testosterone Gel 2% (FE 999303) Equivalent to 23, 46 And 70 mg of Testosterone in Hypogonadal Males
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Testosterone (Primary)
- Indications Hypogonadism
- Focus Therapeutic Use
- Sponsors Ferring Pharmaceuticals
- 16 Aug 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Jun 2011 New trial record